Shares of Biohaven Ltd. (NYSE: BHVN) were soaring 12.7% as of 11:23 a.m. ET on Tuesday after skyrocketing as much as 21.4% earlier in the day. The big gain came after Pfizer (NYSE: PFE) completed its acquisition of Biohaven Pharmaceutical on Monday. The "old" Biohaven, with its migraine drugs Nurtec ODT and zavegepant, became a wholly owned subsidiary of Pfizer.
Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.
NEW YORK, October 04, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinica